Biology subjects

Willinger, O.

Publications and source records attributed to Willinger, O..

5 recordsLinked to original sources

bioRxiv2026

High avidity phase-separated RNA-protein sialogranules sense lectins and inhibit influenza infection

We previously developed synthetic RNA-protein (sRNP) granules as stable, programmable, genetically encoded nanoparticles. Here, we adapt this platform into high-avidity sialogranules that inhibit influenza virus entry. Natural or synthetic 2,6-sialylated proteins and peptides were fused to RNA-binding domains and assembled with synthetic long non-coding RNA to form phase-separated glyco-nanoparticles. Using the sialic-acid-binding lectin Sambucus nigra agglutinin (SNA), we identified a selective transition from sialogranules to tri-component multiphasic biocondensates that occurs only for sialylated constructs. The structural features of this transition quantitatively correlate with predicted sialylation density, enabling extraction of an effective avidity constant. Enzymatic desialylation with neuraminidase or Endo H abolished SNA binding and restored native granule morphology. Guided by this assay, LAMP1-based sialogranules were selected and inhibited influenza entry by [~]50% in cell culture. These results establish sRNP sialogranules as programmable glyco-nanoparticles integrating glycan sensing with antiviral decoy activity.

synthetic biology↗

bioRxiv2026

Synthetic RNA-protein decoy granules to prevent SARS-CoV-2 infection

Synthetic receptor decoys offer a promising strategy to block viral entry but are often limited by instability and rapid clearance. Here we introduce AntiCoV decoy particles: phase-separated synthetic RNA-protein nanoparticles that display multivalent human ACE2 and act as robust decoy receptors for SARS-CoV-2. The granules remain structurally stable for at least two weeks at room temperature. Using confocal imaging and FRET, we show that the SARS-CoV-2 receptor-binding domain is absorbed into the granule matrix with nanometer-scale proximity to ACE2. In viral entry assays with Delta and Omicron (BA.1) variants, AntiCoV decoy particles achieve complete inhibition of infection at low micromolar concentrations and outperform soluble ACE2, which also exhibits infection enhancement at low doses. A minimal kinetic model suggests a multistep spike-priming mechanism that reconciles this biphasic response. AntiCoV decoy particles therefore provide a stable, modular, and pan-variant antiviral platform with potential for low-cost, room-temperature-stable prophylaxis.

synthetic biology↗

bioRxiv2024

Phase Separation-based Antiviral Decoy Particles as Basis for Programmable Broad-spectrum Therapeutics

To gain access to cells, viruses employ host proteins as receptors. In soluble form, these receptors are used as decoys to inhibit infection. We fused candidate soluble receptors to an RNA-binding protein, and using synthetic long non-coding RNA (slncRNA) cassettes that can undergo phase-separation we scaffolded the receptor fusions to generate antiviral decoy particles. Using confocal microscopy, we screened antiviral protein candidates by observing changes in phase-separation morphology when incubated with viral-mimicking components. We demonstrated that ACE2 decoy particles bind strongly to the coronavirus RBD, facilitating FRET, while sufficiently sialylated decoy particles form agglutinated structures with RNA peripheries in the presence of a sialolectin. Infection assays show ACE2 decoy particles fully inhibit the Delta and Omicron BA.1 coronavirus variants, and LAMP1 and GYPA decoy particles significantly reduce influenza infection in-cellulo. This work establishes a foundation for broad-spectrum antiviral decoy particles, composed of multiple receptors targeting various viruses.

synthetic biology↗

bioRxiv2021

A cell-free assay for rapid screening of inhibitors of hACE2-receptor - SARS-CoV-2-Spike binding

We present a cell-free assay for rapid screening of candidate inhibitors of protein binding, focusing on inhibition of the interaction between the SARS-CoV-2 Spike receptor binding domain (RBD) and human angiotensin-converting enzyme 2 (hACE2). The assay has two components: fluorescent polystyrene particles covalently coated with RBD, termed virion-particles (v-particles), and fluorescently-labeled hACE2 (hACE2F) that binds the v-particles. When incubated with an inhibitor, v-particle - hACE2F binding is diminished, resulting in a reduction in the fluorescent signal of bound hACE2F relative to the non-inhibitor control, which can be measured via flow cytometry or fluorescence microscopy. We determine the amount of RBD needed for v-particle preparation, v-particle incubation time with hACE2F, hACE2F detection limit, and specificity of v-particle binding to hACE2F. We measure the dose response of the v-particles to a known inhibitor. Finally, we demonstrate that RNA-hACE2F granules trap v-particles effectively, providing a basis for potential RNA-hACE2F therapeutics.

synthetic biology↗

bioRxiv2019

Identifying triplex binding rules in vitro leads to creation of a new synthetic regulatory tool in vivo

Nature provides a rich toolbox of dynamic nucleic acid structures that are widespread in cells and affect multiple biological processes1. Recently, non-canonical structures gained renewed scientific and biotechnological interest2,3. One particularly intriguing form of such structures are triplexes4 in which a single-stranded nucleic acid molecule interacts via Hoogsteen bonds with a DNA/RNA double helix5. Despite extensive research in vitro6-9, the underlying rules for triplex formation remain debated and evidence for triplexes in vivo is circumstantial10-12. Here, we demonstrate the development of a deep-sequencing platform termed Triplex-Seq to systematically refine the DNA triplex code and identify high affinity triplex forming oligo (TFO) variants. We identified a preference for short G-rich motifs using an oligo-library with a mix of all four bases. These high-information content motifs formed specific high-affinity triplexes in a pH-independent manner and stability was increased with G-rich double-stranded molecules. We then conjugated one high-affinity and one low-affinity variant to a VP48 peptide and studied these synthetic biomolecules in mammalian cells. Using these peptide-oligo constructs (POCs), we demonstrated possible triplex-induced down-regulation activity in 544 differentially expressed genes. Our results show that deep-sequencing platforms can substantially expand our understanding of triplex binding rules, which in turn has led to the development of a functional non-genetically encoded regulatory tool for in vivo applications.

synthetic biology↗